Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Short term Debt (2022 - 2025)

HCW Biologics (HCWB) has disclosed Short term Debt for 4 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt rose 7.36% year-over-year to $6.8 million, compared with a TTM value of $6.8 million through Sep 2025, up 7.36%, and an annual FY2024 reading of $6.3 million, changed N/A over the prior year.
  • Short term Debt was $6.8 million for Q3 2025 at HCW Biologics, up from $6.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $38.3 million in Q4 2022 and bottomed at $67979.0 in Q1 2023.
  • Average Short term Debt over 4 years is $6.4 million, with a median of $6.2 million recorded in 2025.
  • The sharpest move saw Short term Debt surged 5287.93% in 2024, then increased 7.36% in 2025.
  • Year by year, Short term Debt stood at $38.3 million in 2022, then crashed by 99.69% to $117680.0 in 2023, then surged by 5265.98% to $6.3 million in 2024, then increased by 7.8% to $6.8 million in 2025.
  • Business Quant data shows Short term Debt for HCWB at $6.8 million in Q3 2025, $6.4 million in Q2 2025, and $6.2 million in Q1 2025.